<SEC-DOCUMENT>0001104659-24-125129.txt : 20241203
<SEC-HEADER>0001104659-24-125129.hdr.sgml : 20241203
<ACCEPTANCE-DATETIME>20241203172158
ACCESSION NUMBER:		0001104659-24-125129
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20241203
DATE AS OF CHANGE:		20241203

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Coherus BioSciences, Inc.
		CENTRAL INDEX KEY:			0001512762
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				273615821
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36721
		FILM NUMBER:		241523771

	BUSINESS ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		(650) 649-3530

	MAIL ADDRESS:	
		STREET 1:		C/O DENNIS M. LANFEAR
		STREET 2:		333 TWIN DOLPHIN DR, SUITE 600
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioGenerics, Inc.
		DATE OF NAME CHANGE:	20110210
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>tm2429853d3_defa14a.htm
<DESCRIPTION>DEFA14A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="border-top: Black 2pt solid; font-size: 1pt; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B>&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCHEDULE 14A</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Proxy Statement Pursuant to Section&nbsp;14(a)&nbsp;of
the</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Securities Exchange Act of 1934</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Amendment No.&nbsp;)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="border-top: Black 1pt solid; font-size: 1pt">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by the Registrant <FONT STYLE="font-family: Wingdings">&#120;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Filed by a party other than the Registrant <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Check the appropriate box:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD STYLE="width: 97%">Preliminary Proxy Statement</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&NegativeThickSpace;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>&NegativeThickSpace;</B></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD><B>Confidential, for Use of the Commission Only (as permitted by Rule&nbsp;14a-6(e)(2))</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&NegativeThickSpace;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&NegativeThickSpace;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD>Definitive Proxy Statement</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&NegativeThickSpace;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&NegativeThickSpace;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD>Definitive Additional Materials</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&NegativeThickSpace;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&NegativeThickSpace;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD>Soliciting Material under &sect;240.14a-12</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Coherus BioSciences,&nbsp;Inc.</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Registrant as Specified In Its Charter)</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(Name of Person(s)&nbsp;Filing Proxy Statement,
if Other Than The Registrant)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Payment of Filing Fee (Check the appropriate box):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 3%"><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD>
    <TD STYLE="width: 97%">No fee required.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&NegativeThickSpace;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&NegativeThickSpace;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD>Fee paid previously with preliminary materials.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-size: 10pt">&NegativeThickSpace;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&NegativeThickSpace;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD>
    <TD>Fee computed on table in exhibit required by Item 25(b)&nbsp;per Exchange Act Rules&nbsp;14a-6(i)(1)&nbsp;and 0-11.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt"></FONT>This
Schedule 14A relates solely to preliminary communications made prior to furnishing security holders of Coherus BioSciences,&nbsp;Inc.
(the &ldquo;Company&rdquo;) with a definitive proxy statement related to a proposed transaction in which the Company has agreed to divest
its UDENYCA&reg; (pegfilgrastim-cbqv) franchise (the &ldquo;Proposed Transaction&rdquo;) to Intas Pharmaceuticals Ltd. subject to the
terms and conditions set forth in the Asset Purchase Agreement, dated December&nbsp;2, 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Schedule 14A filing consists of the following
documents relating to the Proposed Transaction:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD>Employee FAQ</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD>Field Direction Memo</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>3.</TD><TD>Employee Email</TD></TR>
                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>4.</TD><TD>Analyst Email</TD></TR>
                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>5.</TD><TD>Investor Email</TD></TR>
                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                  <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>6.</TD><TD>Commercial Team Email</TD></TR>
                                                                                                  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;<IMG SRC="tm2429853d3_defa14aimg001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">For Selected Coherus
Employees Who Wish to Transfer to the Accord Family Frequently Asked Questions &ndash; FAQs</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">December&nbsp;3,
2024</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">As we move toward
the closing of the acquisition of the UDENYCA business by Intas Pharmaceuticals Ltd. (&ldquo;Intas&rdquo;) as contemplated by the
asset purchase agreement between Coherus BioSciences,&nbsp;Inc. (&ldquo;Coherus&rdquo;) and Intas,&nbsp;Intas&rsquo; U.S.
subsidiary, Accord Biopharma &amp; Coherus want to provide responses to some frequently asked questions that selected Coherus
employees may have as they consider whether they wish to become part of the Accord family.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">Accord is excited
to welcome selected Coherus Employees who wish to transfer to Accord effective on the day of closing and they are here to support you
should you choose to make that transition. Until the closing, selected Coherus employees who will transfer to Accord should please continue
to report to your Coherus manager and direct any other questions not covered in this document to Rebecca Sunshine, Human Resources.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-size: 10pt">Everything is &ldquo;business
as usual&rdquo; for UDENYCA and Loqtorzi, and employees should remain focused and not get distracted by this deal announcement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border: Black 1pt solid; width: 45%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Question</B></FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; width: 55%; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Answer</B></FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">If
                                            I am transferring to Accord, will I receive an Offer Letter from Accord?</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Accord
                                            is excited to offer selected employees an opportunity to build and expand the Udenyca franchise.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">There are customary conditions which
    need to be cleared, and Coherus shareholder approval required to approve the sale. The transaction is expected to close in Q1 2025.
    Accord is happy to provide opportunities for Coherus employees to join them to continue to work with UDENYCA in early 2025. Selected
    employees will have an opportunity to meet with the Accord hiring team in mid-January&nbsp;or February&nbsp;2025. All transferring
    associates will receive a Contingency Offer Letter.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The Contingency Offer letter will
    provide specifics about your employment as well as conditions and agreements you will be required to adhere to. The letter must be
    signed and returned within the timeframe the letter provides if you wish to accept the terms of employment with Accord. More details
    will be shared in early 2025.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">

<TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">Why
    is shareholder approval required for this transaction, but was not required for the recent divestitures of Cimerli or Yusimry?</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; width: 55%"><FONT STYLE="font-size: 10pt">Coherus
    is seeking approval from its shareholders before the closing because UDENYCA is a large enough asset, shareholder approval may be
    required before we sell it according to Delaware General Corporation Law.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Because
    Accord headquarters are in Raleigh, North Carolina, will I have to move?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Post-deal
                                            closing, for Coherus employees who wish to join the Accord family, no one will be required
                                            to relocate at this time. Accord understands and is sensitive to the current location and
                                            working situation for each Coherus employee. Accord is open to transfers and will handle
                                            these requests on a case-by-case basis.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">What
    will happen to my pay and benefits?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Should
                                            selected employees decide to join the Accord team, their employment with them will begin
                                            on the day of deal close. You will transition to the Accord payroll and benefits programs
                                            at that time. There will be no interruption to your pay schedule. Please be assured Accord&rsquo;s
                                            HR department will be available to assist you with this transition and answer any questions
                                            you may have.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">What
    will happen to my Coherus stock options?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">More
                                            information will be provided in Q1 2025.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Will
    Accord give us stock options?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The
                                            Accord group of companies are privately held. We value our employees and offer a comprehensive
                                            compensation and benefits package that is competitive within the pharma industry. At this
                                            time Accord does not have stock options.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">What
    will happen to my ESPP deductions?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The
                                            next ESPP purchase date is May&nbsp;15, 2025, so selected employees who will transfer to
                                            Accord and who currently participate in ESPP, ESPP deductions for the current period will
                                            be refunded to you when you join Accord.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Does
    Accord have an ESPP Plan?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Not
                                            at this time.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">What
                                            happens to my Paid Time Off in ADP?</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Should
                                            selected employees accept the position offered by Accord PTO hours will be paid out on your
                                            last day with Coherus.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">I
    have a planned vacation that was already submitted to ADP, will I still be able to go?</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 55%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Coherus
                                            and Accord will honor any prior approved vacation days. Future requests must be aligned with
                                            Accord&rsquo;s PTO policy and their process.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Will
    I accrue vacation after close and will I be able to take new vacation?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Selected
                                            employees will join the Accord PTO plan as of their new hire date, the day of closing, and
                                            will begin to accrue PTO on the plan at that time. Your accrual will be prorated for the
                                            first year of employment, based off your new hire date, but your original hire date with
                                            Coherus will be used to determine your tenure and subsequent accrual rate under the plan.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">If
    I am on the Quarterly Field-Based Incentive Plan, will I still get my Q4-2024 bonus?</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Yes.&nbsp;&nbsp;Coherus
    plans to pay any earned Q4 2024 IC bonus.</FONT></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">If
    I am on the Corporate Bonus Plan, will I get my 2024 corporate bonus?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The
                                            Coherus BOD has not yet approved our 2024 corporate bonus, but if one is approved, you will
                                            receive it the same as all other employees on that plan.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Coherus
    salary increases for the field is April&nbsp;1<SUP>st</SUP> and for corporate is July&nbsp;1<SUP>st</SUP>, when are salary increases
    at Accord?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Annual
                                            merit increases are evaluated and granted at the end of Accord&rsquo;s fiscal year, which
                                            runs April&nbsp;1st to March&nbsp;30th. Once transitioned, selected employees annual merit
                                            will be evaluated on April&nbsp;1 each year.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">What
    will happen to my 2024 Chairman&rsquo;s Circle ranking?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Selected
                                            employees will still be ranked and rewarded according to the 2024 Chairman&rsquo;s Circle
                                            program.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">What
    will happen to my $7,500 401K Match for 2024?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Since
                                            selected employees will be a Coherus employee through the end of 2024, the 401K match will
                                            be received at the end of March&nbsp;2025.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">What
    do I do with my Coherus laptop, iPad, printer, monitors,&nbsp;etc.?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The
                                            Coherus HR team will work to collect all Coherus equipment, post close. Until the date of
                                            closing, you will continue to be a Coherus employee using Coherus equipment.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">What
    will happen to my Coherus data and files?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Selected
                                            employees&rsquo; Coherus confidential information, trade secrets, data and files belong to
                                            Coherus, and is governed by the PIIA signed, so you will no longer have access to them when
                                            you join Accord. Coherus and Accord IT are currently reviewing, and Accord IT will provide
                                            more information during your onboarding.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">Will
    I still have access to my tax documents in ADP after I join Accord?</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; font-size: 10pt; padding-right: 5.4pt; padding-left: 5.4pt; width: 55%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Selected
                                            employees&rsquo; access to ADP Workforce Now will continue for 3 years after their last day
                                            at Coherus.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Do
    I need to complete a new W4 when my employment transfers to Accord?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Selected
                                            employees will undergo HR onboarding when you join Accord, including validating all tax withholding
                                            information, should you choose to do so.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">What
                                            happens if I need to submit an expense report after my last day at Coherus?</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">If
                                            selected employees are not able to complete all expense reports prior to your last day with
                                            Coherus, the Company will allow up to 4 weeks following their last day to email a list of
                                            your expenses, with copies of their receipts, to the payroll department at: [***].</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Will
    I be issued a new Accord Corporate Credit Card?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">If
                                            selected employees&rsquo; role at Accord requires a corporate credit card, one will be issued.
                                            You will be able to work with your Accord Manager and Finance team to be issued an Accord
                                            Corporate Card.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">What
    if I need to travel for Accord?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Accord
                                            has a documented travel policy that will be shared at the time of employment.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Will
    I be issued a new ID Badge?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Accord
                                            employees who will require access to Accord corporate office in Raleigh, NC will be issued
                                            a badge to the corporate office in Raleigh.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">What
    do I say to customers who call with concerns because of the deal?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">According
                                            to Coherus&rsquo;s policies, employees should not make comments about the proposed transaction.
                                            Coherus is continuing to operate business as usual until the deal closes. Accord will be
                                            providing talking points and customer communication at the HR onboarding.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">When
    am I able to update my LinkedIn profile?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Selected
                                            employees may update their LinkedIn profile to reflect employment with Accord after the deal
                                            closing has been publicly announced. According to Coherus policies, no one except authorized
                                            spokespersons are approved to make announcements or posts about Coherus on social media.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt; width: 45%"><FONT STYLE="font-size: 10pt">What
    should I do if someone from the media calls to ask about the deal?</FONT></TD>
    <TD STYLE="border-top: Black 1pt solid; font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; width: 55%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">If
                                            you are contacted by anyone with questions, either internally or externally, people, please
                                            refer them to Rebecca Sunshine at [***] Jodi Sievers at [***] or Nuvan Dassanaike at Accord
                                            at [***].</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Accord has established an internal
    email for all integration-related questions:</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">Who
    should I contact if I have additional questions?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Please
                                            contact Rebecca at [***] if you have additional questions.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  <TR STYLE="font-size: 10pt; vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt; font-size: 10pt"><FONT STYLE="font-size: 10pt">How
    do I access my FSA, 401K, W-2,&nbsp;etc.?</FONT></TD>
    <TD STYLE="font-size: 10pt; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">There
                                            will be a separate Benefits FAQ for specific details and website logins to access all your
                                            benefits plans, 401K rollover,&nbsp;etc.</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Other Important Reminders <U>for
All Coherus Employees</U></B>: Please continue business as usual with UDENYCA, but be mindful of what you say outside of the company&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>Do
                                            not disclose</B> any know-how or confidential information to <B>Accord BioPharma, Inc</B>.
                                            prior to deal close. This includes any information on customers, contracts, commercial performance,
                                            etc.</FONT></TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">If you <B>receive any inquiries</B> about this
                                            deal or the UDENYCA transition - even from Accord BioPharma representatives - please direct
                                            them to Rebecca Sunshine and Paul Reider</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Keep <B>all internal and external e-mail, text,
                                            and other interactions</B> regarding the UDENYCA divestiture to a minimum and to the normal
                                            course of business</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify"><B>No social media</B> activity regarding the
                                            deal, including as it may relate to UDENYCA or Accord BioPharma. This includes posting on
                                            your personal social media channels, or engaging with the posts of others by commenting,
                                            liking, sharing, retweeting, etc.</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
     <TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Employees are <B>not permitted to provide comments</B>,
                                            whether on background or on the record, or otherwise respond to third party inquiries</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The statements in this communication
include express or implied forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E
of the Exchange Act about the proposed transaction between the Company and Intas that involve risks and uncertainties relating to future
events and the future performance the Company and the UDENYCA business. Forward-looking statements relate to expectations, beliefs, projections,
future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. Words
such as &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo;
 &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo;
 &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;future,&rdquo; &ldquo;opportunity,&rdquo; &ldquo;likely,&rdquo; &ldquo;target,&rdquo;
variations of such words, and similar expressions or negatives of these words are intended to identify such forward-looking statements,
although not all forward-looking statements contain these identifying words. You can also identify forward-looking statements by discussions
of strategy, plans or intentions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Examples of such forward-looking statements
include, but are not limited to, express or implied statements regarding: the asset purchase agreement and related matters, including,
but not limited to, satisfaction of closing conditions to consummate the proposed transaction, prospective performance and opportunities
with respect to the Company or the UDENYCA business, post-closing operations and the outlook for the Company or the UDENYCA business;
future bonus payments and treatment of Coherus stock options; information about future employment with Accord, and the assumptions underlying
or relating to such statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">These forward-looking statements are
based on the Company&rsquo;s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent
risks and uncertainties, both general and specific, assumptions and changes in circumstances, many of which are beyond the control of
the Company. A number of important factors, including those described in this communication, could cause actual results to differ materially
from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking
statements to be inaccurate include, without limitation: uncertainties as to the timing for completion of the proposed transaction; uncertainties
as to the Company&rsquo;s ability to obtain the approval of its stockholders required to consummate the proposed transaction; the possibility
that competing offers will be made by third parties; uncertainties of payment of the earn-outs in the future; the occurrence of any event,
change or other circumstance that may give rise to a right of one or both of Intas and the Company to terminate the Asset Purchase Agreement;
the possibility that the proposed transaction may not be completed in the time frame expected by the Company including on a timely basis
or at all, including due to the possibility that a governmental entity may prohibit, delay, or refuse to grant approval, if required,
for the consummation of the proposed transaction (or only grant approval subject to adverse conditions or limitations);; the proposed
transaction disrupts the Company&rsquo;s current plans and operations or diverts the attention of the Company&rsquo;s management or employees
from ongoing business operations; the risk that the Company may not realize the anticipated benefits of the proposed transaction in the
time frame expected, or at all; the effects of the proposed transaction on relationships with the Company&rsquo;s employees, suppliers,
business or collaboration partners or governmental entities, or other third parties as a result of the proposed transaction; the ability
to retain and hire key personnel; significant or unexpected costs, charges or expenses resulting from the proposed transaction; the potential
impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, economic performance, indebtedness,
financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of
the Company after the consummation of the proposed transaction; potential negative effects related to this announcement or the consummation
of the proposed transaction on the market price of the Company&rsquo;s common stock and/or the Company&rsquo;s operating or financial
results; uncertainties as to the long-term value of the Company&rsquo;s common stock; and the nature, cost and outcome of any litigation
and other legal proceedings involving the transaction, the Company or its directors, including any legal proceedings related to the proposed
transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">While the foregoing list of factors
presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties.
There can be no assurance that the transaction described above will in fact be consummated in the manner described or at all. For a further
discussion of these and other factors that could cause the Company&rsquo;s future results to differ materially from any forward-looking
statements see the section entitled &ldquo;Risk Factors&rdquo; in the Company&rsquo;s Quarterly Report on Form&nbsp;10-Q for the period
ended September&nbsp;30, 2024, filed with the SEC on November&nbsp;6, 2024, as updated by the Company&rsquo;s subsequent periodic reports
filed with the SEC and, when available, the proxy statement of the Company relating to the proposed transaction. Any forward-looking
statements speak only as of the date of this communication and are made based on the current good faith beliefs and judgments of the
Company&rsquo;s management, and the reader is cautioned not to rely on any forward-looking statements made by the Company. Unless required
by law, the Company is not under any duty and undertakes no obligation to publicly update or revise any forward-looking statement to
reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Additional Information and Where
to Find It</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">In connection with the proposed transaction,
the Company expects to file with the SEC a proxy statement on Schedule 14A, and it may also file other documents regarding the proposed
transaction with the SEC. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the definitive proxy
statement and a proxy card to each stockholder entitled to vote at the special meeting relating to the proposed transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">INVESTORS AND SECURITY HOLDERS ARE URGED
TO READ CAREFULLY THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS
THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN,&nbsp;IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN
OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION, RELATED MATTERS AND THE PARTIES TO THE PROPOSED TRANSACTION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">You may obtain a free copy of the proxy
statement and other relevant documents (if and when they become available) that are or will be filed with the SEC for free at the SEC&rsquo;s
website at www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on the Company&rsquo;s
website at&nbsp;https://investors.coherus.com/sec-filings&nbsp;or by contacting the Company&rsquo;s Investor Relations Department at
<U>IR@coherus.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Participants in the Solicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The Company and certain of its directors
and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies
in respect of the proposed transaction. Information about the directors and executive officers of the Company, including a description
of their direct or indirect interests, by security holdings or otherwise, is set forth in the proxy statement for its 2024 Annual General
Meeting, which was filed with the SEC on April&nbsp;15, 2024&nbsp;and other documents that may be filed from time to time with the SEC.
Other information regarding the participants in the proxy solicitations and a description of their direct and indirect interests in the
proposed transaction, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be
filed with the SEC regarding the proposed transaction when such materials become available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2429853d3_defa14aimg002.jpg" ALT=""></FONT></TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2429853d3_defa14aimg003.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Field
Direction Memo</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>Date:</B></FONT></TD>
  <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-size: 10pt"><B>December&nbsp;3, 2024</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt"><B>From:</B></FONT></TD>
  <TD STYLE="padding-left: 0.25in"><FONT STYLE="font-size: 10pt"><B>Paul Reider</B></FONT></TD></TR>

<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-align: center; font-size: 10pt; width: 8%"><FONT STYLE="font-size: 10pt"><B>Subject:</B></FONT></TD><TD STYLE="padding-left: 0.25in; font-size: 10pt; width: 92%"><FONT STYLE="font-size: 10pt"><B>Coherus Divestiture of UDENYCA<SUP>&reg;
                                            </SUP>Franchise to Intas Pharmaceuticals</B></FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-align: center; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>To:</B></FONT></TD><TD STYLE="padding-left: 0.25in; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Commercial Team</B> - Oncology Regional
                                            Sales Directors (RSDs), Oncology Account Managers (OAMs), Strategic Accounts (KADs), Payer
                                            Directors, Field Reimbursement Managers (FRMs), Commercial Home Office Personnel</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="text-align: center; border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>CC:</B></FONT></TD><TD STYLE="padding-left: 0.25in; border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Legal, Medical Affairs, HR, Sales,
                                            and Marketing Leadership</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Dear Commercial Team,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">As you are now aware, Coherus announced
the divestiture of UDENYCA&reg; (pegfilgrastim-cbqv) Franchise for up to $558 million to Intas Pharmaceuticals Ltd and its U.S. subsidiary,
Accord BioPharma, who will market UDENYCA. This represents the successful culmination of our strategy to focus R&amp;D and commercial
resources on Coherus&rsquo; innovative immuno-oncology (I/O) portfolio and restructure the company to strengthen our financial position.
Coherus will continue to fully operate the UDENYCA business until the transaction closes, which is expected to occur by the end of Q1
2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Over the last 6 years, your efforts
created significant value with our UDENYCA franchise, and this transaction allows us to maximize the opportunity ahead for LOQTORZI (toripalimab-tpzi),
a novel PD-1 inhibitor with growing sales, and the only FDA approved treatment for nasopharyngeal carcinoma (NPC), allowing us to accelerate
and advance the development of our I/O pipeline in combination with LOQTORZI.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Key Takeaways Related to This Transaction:
FOR INTERNAL COMMUNICATION PURPOSES ONLY</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coherus
                                            to focus exclusively on innovative immuno-oncology programs with LOQTORZI&reg;, an FDA approved,
                                            next-generation programmed cell death protein 1 (PD-1) inhibitor</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proceeds
                                            to drive development of key LOQTORZI combination programs, including casdozokitug, a first-in-class,
                                            clinical-stage interleukin-27 (IL-27) antagonist, and CHS-114, a highly selective chemokine
                                            receptor 8 (CCR8) antibody</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-closing
                                            proceeds to repay, not restructure, $230 million in existing convertible debt due April&nbsp;2026
                                            and $49.1 million to buy-out certain royalty obligations related to UDENYCA</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2429853d3_defa14aimg002.jpg" ALT=""></FONT></TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2429853d3_defa14aimg003.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Remember</B>: The deal has not closed,
and while we are in a business transition stage, please continue day to day activities as usual with UDENYCA, and be mindful of what
you say outside of the company</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Do
                                            not disclose </B>any know-how or confidential information to <B>Accord BioPharma,&nbsp;Inc.
                                            </B>prior to deal close. This includes any information on customers, contracts, commercial
                                            performance,&nbsp;etc.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
                                            you <B>receive any inquiries</B> about this deal or the UDENYCA transition &ndash; even from
                                            Accord BioPharma representatives &ndash; please direct them to Rebecca and Paul</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Keep
                                            <B>all internal and external e-mail, text, and other interactions</B> regarding the UDENYCA
                                            divestiture to a minimum and to the normal course of business</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>No
                                            social media</B> activity regarding the deal, including as it may relate to UDENYCA or Accord
                                            BioPharma. This includes posting on your personal social media channels, or engaging with
                                            the posts of others by commenting, liking, sharing, retweeting,&nbsp;etc.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Employees
                                            are <B>not permitted to provide comments</B>, whether on background or on the record, or
                                            otherwise respond to third party inquiries</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>CALL TO ACTION:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Inform
                                            customers as appropriate re: divestiture announcement; use approved Q&amp;A</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UDENYCA</B>:
                                            <B>Accelerate Re-Supply Plan and Drive Q4/Q1 Sales</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.75in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Engage territory customers sharing re-supply
                                            timelines and any appropriate pricing or contracting changes (per approved materials) and
                                            encourage proactive customer communication with wholesalers regarding re-stocking requirements.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.75in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Strong cross-functional communication
                                            (Sales, KAD, GPO, Marketing) &ndash; continue to share questions/concerns, customer feedback,
                                            and competitor intelligence.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.25in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LOQTORZI:
                                            Meet / Exceed Q4 Goal - Execute plans to accelerate new patient starts for eligible NPC patients</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">If you have any questions, please contact
Paul Reider [***] or Rebecca Sunshine [***].&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Thank you,&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Paul</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2429853d3_defa14aimg002.jpg" ALT=""></FONT></TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2429853d3_defa14aimg003.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>PROACTIVE TALKING POINTS WITH
CUSTOMERS:</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coherus
                                            BioSciences,&nbsp;Inc. (NASDAQ: CHRS) announced on Tuesday December&nbsp;3, 2024, the divestiture
                                            of the UDENYCA&reg; (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals Ltd (Intas).
                                            The business will be operated by Accord BioPharma,&nbsp;Inc. (Accord) the U.S. subsidiary
                                            of Intas.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
                                            transaction allows Coherus to sharpen focus and maximize the opportunity ahead for LOQTORZI&reg;
                                            and to accelerate the development of our I/O pipeline in combination with LOQTORZI.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coherus
                                            will continue to operate the UDENYCA business until the transaction closes, which is expected
                                            by the end of Q1 2025.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Coherus
                                            remains invested in the success of UDENYCA and will work closely with Accord to ensure seamless
                                            transition with customers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B><U>CUSTOMER FOCUSED FAQ&rsquo;s &mdash;
REACTIVE</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Q: Do I need to delay re-instating
                                            UDENYCA back into my practice until after the divesture closes?</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">No.&nbsp;
                                            This transaction, if approved, isn&rsquo;t expected to close until the end of Q1 2025. Until
                                            the transaction closes, Coherus will continue to fully operate the UDENYCA business, and
                                            the terms of your current UDENYCA contract remain unchanged.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Now
                                            that re-supply is underway, you can now re-order UDENYCA and begin prescribing to patients.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">REINFORCE
                                            UDENYCA&rsquo;s APPROVED SELLING MESSAGES, contract terms and payer coverage</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Q: How will this change in ownership
                                            impact me and/or my Clinic / Hospital / Payer?</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Until
                                            the transaction closes, expected to happen in Q1 2025, Coherus will continue to fully operate
                                            the UDENYCA business, and the terms of your current UDENYCA contract remain unchanged.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">After
                                            the deal closes, the Coherus contracts will remain in place during a transition period, so
                                            you have an opportunity to enter into agreements with Accord.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Both
                                            Coherus and Accord are committed to the long-term success of the UDENYCA franchise and will
                                            work closely with you to ensure the seamless transition of UDENYCA contracts after the deal
                                            closes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Q:&nbsp; Will there be any changes
                                            to the UDENYCA provider or patient support programs?</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">There
                                            will not be any immediate changes to the UDENYCA patient support program.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Please
                                            continue utilizing the same PSP contacts and contact numbers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Q: Will there be any staffing changes
                                            that might affect me and/or my Clinic / Hospital / Payer?</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Until
                                            the deal closes, the Coherus team will continue to support UDENYCA.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">If
                                            there are staffing changes post-close, Coherus and Accord will work closely with you to ensure
                                            a seamless transition.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Q: Will this impact the UDENYCA re-supply
                                            timelines?</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">No.&nbsp;
                                            Coherus and Accord remain fully committed to the short- and long-term supply of UDENYCA.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">You
                                            can now begin to re-order UDENYCA. Contact your wholesaler to inform them of your plans.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Q: Are the contracts/purchase orders
                                            we have in place still valid? If so, for how long?</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">The
                                            terms of your current UDENYCA contract remain unchanged until the deal closes.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Both
                                            Coherus and Accord are committed to the long-term success of the UDENYCA franchise and will
                                            work closely with you to ensure the seamless transition of UDENYCA contracts after the deal
                                            closes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Q: How is manufacturing/supply going
                                            to be handled post-deal close?</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Coherus
                                            and Accord remain fully committed to the short- and long-term supply of UDENYCA and will
                                            work closely to ensure the transition of all UDENYCA manufacturing to Accord.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Accord&rsquo;s
                                            parent Company,&nbsp;Intas, has been developing, manufacturing, and marketing biologics for
                                            more than 20 years.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>ACTION:
                                            </B>Send customer the link to access the Re-Supply Status document for real time updates.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2429853d3_defa14aimg002.jpg" ALT=""></FONT></TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2429853d3_defa14aimg003.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Q: How do I order UDENYCA?</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Continue
                                            to order UDENYCA through your current processes and systems.</FONT></TD></TR>
<TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">That
                                            said, both Coherus and Accord are committed to the long-term success of the UDENYCA franchise
                                            and will inform you of any changes to ordering once the deal closes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Q: Who do I call if I have a problem
                                            or concern?</B></FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="font-size: 10pt; vertical-align: top">
<TD STYLE="font-size: 10pt; width: 0.5in"></TD><TD STYLE="font-size: 10pt; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">o</FONT></TD><TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">For
                                            now, continue to work with your current Coherus representative.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2429853d3_defa14aimg002.jpg" ALT=""></FONT></TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2429853d3_defa14aimg003.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Email Template</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">TO&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[Customer email address]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">FROM&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[Coherus employee email address]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">SUBJECT&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Coherus Announces Divestiture of UDENYCA&reg;
Franchise to Intas Pharmaceuticals Ltd.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Dear [Customer Name, credential]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">I am writing to inform you that Coherus
BioSciences,&nbsp;Inc. (NASDAQ: CHRS) announced on Tuesday December&nbsp;3, 2024, the divestiture of the UDENYCA&reg; (pegfilgrastim-cbqv)
franchise to Intas Pharmaceuticals,&nbsp;Ltd. and its U.S. subsidiary Accord BioPharma. Coherus remains invested in the success of UDENYCA
and will continue to operate the business until the transaction closes, which is anticipated to close by the end of Q1 2025. Following
the close, Coherus will work closely with the Accord team to ensure seamless transition with customers. This transaction allows Coherus
to sharpen our focus on LOQTORZI&reg; <FONT STYLE="font-family: Times New Roman, Times, Serif">(toripalimab-tpzi), </FONT>to accelerate
the development of our I/O pipeline in combination with LOQTORZI, and to restructure the company to strengthen our financial position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Please note that until the deal closes,
the Coherus team will continue to support UDENYCA and there will not be any immediate changes to the UDENYCA contracts or patient support
program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">I would be happy to set up additional
time to meet with you or a member of your staff if you have any further questions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Thank you,&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">[Field representative email signature]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Additional Information and Where
to Find It</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">In connection with the proposed transaction,
the Company expects to file with the SEC a proxy statement on Schedule 14A, and it may also file other documents regarding the proposed
transaction with the SEC. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the definitive proxy
statement and a proxy card to each stockholder entitled to vote at the special meeting relating to the proposed transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2429853d3_defa14aimg002.jpg" ALT=""></FONT></TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2429853d3_defa14aimg003.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">INVESTORS AND SECURITY HOLDERS ARE URGED
TO READ CAREFULLY THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS
THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN,&nbsp;IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN
OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION, RELATED MATTERS AND THE PARTIES TO THE PROPOSED TRANSACTION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">You may obtain a free copy of the proxy
statement and other relevant documents (if and when they become available) that are or will be filed with the SEC for free at the SEC&rsquo;s
website at www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on the Company&rsquo;s
website at https://investors.coherus.com/sec-filings or by contacting the Company&rsquo;s Investor Relations Department at IR@coherus.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Participants in the Solicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The Company and certain of its directors
and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies
in respect of the proposed transaction. Information about the directors and executive officers of the Company, including a description
of their direct or indirect interests, by security holdings or otherwise, is set forth in the proxy statement for its 2024 Annual General
Meeting, which was filed with the SEC on April&nbsp;15, 2024 and other documents that may be filed from time to time with the SEC. Other
information regarding the participants in the proxy solicitations and a description of their direct and indirect interests in the proposed
transaction, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with
the SEC regarding the proposed transaction when such materials become available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">If you have any questions, please contact
John Holland [***] or Cole McIlwraith [***].</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>Thank you,</I>&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><I>The UDENYCA Marketing Team</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Forward-Looking Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The statements in this communication
include express or implied forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E
of the Exchange Act about the proposed transaction between Coherus BioSciences,&nbsp;Inc. (the &ldquo;Company&rdquo;) and Intas Pharmaceuticals
Ltd. (&ldquo;Intas&rdquo;) that involve risks and uncertainties relating to future events and the future performance of the Company and
the UDENYCA business. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated
events or trends and similar expressions concerning matters that are not historical facts. Words such as &ldquo;will,&rdquo; &ldquo;could,&rdquo;
 &ldquo;would,&rdquo; &ldquo;should,&rdquo; &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo;
 &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo; &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo;
 &ldquo;future,&rdquo; &ldquo;opportunity,&rdquo; &ldquo;likely,&rdquo; &ldquo;target,&rdquo; variations of such words, and similar expressions
or negatives of these words are intended to identify such forward-looking statements, although not all forward-looking statements contain
these identifying words. You can also identify forward-looking statements by discussions of strategy, plans or intentions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">Examples of such forward-looking statements
include, but are not limited to, express or implied statements regarding: the asset purchase agreement and related matters, including,
but not limited to, satisfaction of closing conditions to consummate the proposed transaction, prospective performance and opportunities
with respect to the Company or the UDENYCA business, post-closing operations and the outlook for the Company or the UDENYCA business;
information about future employment with Intas, statements about the re-supply of UDENYCA following the recent supply interruption and
the assumptions underlying or relating to such statements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2429853d3_defa14aimg002.jpg" ALT=""></FONT></TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2429853d3_defa14aimg003.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">These forward-looking statements are
based on the Company&rsquo;s current plans, estimates and projections. By their very nature, forward-looking statements involve inherent
risks and uncertainties, both general and specific, assumptions and changes in circumstances, many of which are beyond the control of
the Company. A number of important factors, including those described in this communication, could cause actual results to differ materially
from those contemplated in any forward-looking statements. Factors that may affect future results and may cause these forward-looking
statements to be inaccurate include, without limitation: uncertainties as to the timing for completion of the proposed transaction; uncertainties
as to the Company&rsquo;s ability to obtain the approval of its stockholders required to consummate the proposed transaction; the possibility
that competing offers will be made by third parties; uncertainties of payment of the earn-outs in the future; the occurrence of any event,
change or other circumstance that may give rise to a right of one or both of Intas and the Company to terminate the Asset Purchase Agreement;
the possibility that the proposed transaction may not be completed in the time frame expected by the Company including on a timely basis
or at all, including due to the possibility that a governmental entity may prohibit, delay, or refuse to grant approval, if required,
for the consummation of the proposed transaction (or only grant approval subject to adverse conditions or limitations); the proposed
transaction disrupts the Company&rsquo;s current plans and operations or diverts the attention of the Company&rsquo;s management or employees
from ongoing business operations; the risk that the Company may not realize the anticipated benefits of the proposed transaction in the
time frame expected, or at all; the effects of the proposed transaction on relationships with the Company&rsquo;s employees, suppliers,
business or collaboration partners or governmental entities, or other third parties as a result of the proposed transaction; the ability
to retain and hire key personnel; significant or unexpected costs, charges or expenses resulting from the proposed transaction; the potential
impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, economic performance, indebtedness,
financial condition and losses on the future prospects, business and management strategies for the management, expansion and growth of
the Company after the consummation of the proposed transaction; potential negative effects related to this announcement or the consummation
of the proposed transaction on the market price of the Company&rsquo;s common stock and/or the Company&rsquo;s operating or financial
results; uncertainties as to the long-term value of the Company&rsquo;s common stock; and the nature, cost and outcome of any litigation
and other legal proceedings involving the transaction, the Company or its directors, including any legal proceedings related to the proposed
transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">While the foregoing list of factors
presented here is considered representative, no list should be considered to be a complete statement of all potential risks and uncertainties.
There can be no assurance that the transaction described above will in fact be consummated in the manner described or at all. For a further
discussion of these and other factors that could cause the Company&rsquo;s future results to differ materially from any forward-looking
statements see the section entitled &ldquo;Risk Factors&rdquo; in the Company&rsquo;s Quarterly Report on Form&nbsp;10-Q for the period
ended September&nbsp;30, 2024, filed with the SEC on November&nbsp;6, 2024, as updated by the Company&rsquo;s subsequent periodic reports
filed with the SEC and, when available, the proxy statement of the Company relating to the proposed transaction. Any forward-looking
statements speak only as of the date of this communication and are made based on the current good faith beliefs and judgments of the
Company&rsquo;s management, and the reader is cautioned not to rely on any forward-looking statements made by the Company. Unless required
by law, the Company is not under any duty and undertakes no obligation to publicly update or revise any forward-looking statement to
reflect changes in underlying assumptions or factors, of new information, data or methods, future events or other changes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Additional Information and Where
to Find It</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">In connection with the proposed transaction,
the Company expects to file with the SEC a proxy statement on Schedule 14A, and it may also file other documents regarding the proposed
transaction with the SEC. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the definitive proxy
statement and a proxy card to each stockholder entitled to vote at the special meeting relating to the proposed transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">INVESTORS AND SECURITY HOLDERS ARE URGED
TO READ CAREFULLY THE PROXY STATEMENT AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS
THERETO AND ANY DOCUMENTS INCORPORATED BY REFERENCE THEREIN,&nbsp;IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN
OR WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION, RELATED MATTERS AND THE PARTIES TO THE PROPOSED TRANSACTION.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: left; width: 50%"><FONT STYLE="font-size: 10pt"><IMG SRC="tm2429853d3_defa14aimg002.jpg" ALT=""></FONT></TD>
  <TD STYLE="text-align: right; width: 50%"><IMG SRC="tm2429853d3_defa14aimg003.jpg" ALT=""><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">You may obtain a free copy of the proxy
statement and other relevant documents (if and when they become available) that are or will be filed with the SEC for free at the SEC&rsquo;s
website at www.sec.gov. Copies of the documents filed with the SEC by the Company will be available free of charge on the Company&rsquo;s
website at https://investors.coherus.com/sec-filings or by contacting the Company&rsquo;s Investor Relations Department at IR@coherus.com.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt"><B>Participants in the Solicitation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">The Company and certain of its directors
and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies
in respect of the proposed transaction. Information about the directors and executive officers of the Company, including a description
of their direct or indirect interests, by security holdings or otherwise, is set forth in the proxy statement for its 2024 Annual General
Meeting, which was filed with the SEC on April&nbsp;15, 2024 and other documents that may be filed from time to time with the SEC. Other
information regarding the participants in the proxy solicitations and a description of their direct and indirect interests in the proposed
transaction, by security holdings or otherwise, will be contained in the proxy statement and other relevant materials to be filed with
the SEC regarding the proposed transaction when such materials become available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To: All Coherus Employee Email</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From: Denny Lanfear</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Tuesday, December&nbsp;3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject: Udenyca Divestiture Announcement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Coherus Team Members,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This morning, we announced the divestiture of the UDENYCA&reg; franchise
to Intas Pharmaceuticals Ltd. for up to $558 million. Coherus will continue to fully operate the UDENCYA business until the transaction
closes, which is expected toward the end of Q1 2025.Following that,&nbsp;Intas&rsquo; U.S. subsidiary, Accord, will market the product,
supported by Coherus during a transition period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Let me describe for you the rationale for the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">First, this transaction represents the successful completion of our
long-term strategy to focus our Commercial and R&amp;D resources on immuno-oncology, on our PD-1 Loqtorzi, and novel combinations of LOQTORZI
with a number of other agents. As you know, since in-licensing our LOQTORZI in early 2021 from Junshi we have pursued an overarching strategy
to enhance long-term shareholder value by leveraging our biosimilar business to build a highly competitive and sustainable innovative
oncology franchise. After closing the Surface Oncology acquisition just over a year ago, then divesting Cimerli and Yusimry, this divestiture
is the definitive step in that direction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Secondly, this transaction allows us to monetize and re-deploy the
significant value we have created with our UDENYCA franchise to maximize the opportunity ahead for our I-O portfolio. The Udenyca OnBody
is highly competitively positioned, raising the brand above others and the catalyst for greater sales. But to realize the franchise&rsquo;s
maximal long term value a larger, more global organization with multiple biosimilars products in the portfolio is required. There is perhaps
greater value in Udenyca in such hands than in our own.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Third, we must maximize the I/O opportunity because that is how we
will both deliver increased patient survival benefit in tough cancers and drive significant value for our shareholders. This means continuing
to build commercial momentum with LOQTORZI in NPC, as well as advance our differentiated and diversified pipeline of immunotherapies across
a number of single agent and combination mid-stage clinical studies in areas of high unmet need, including HCC, HNSCC, lung and gastric
cancers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Coherus was a pioneer in biosimilars in the United States. Our Commercial
team has done an exemplary job up and down the line, out competing and out performing competitors. I am very proud of the significant
value we have created with the UDNECYA franchise, both for patients and for Coherus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">As a result of the Udenyca transaction, we will have a significantly
improved capital structure, as we can now pay down a significant majority of our debt which incurred at the start of Covid. This will
reduce interest payments, and costs. It will allow the stock to trade freely.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Until the deal closes, it is very important that all team members remain
focused on &ldquo;business as usual.&rdquo; Thank you for your commitment to Coherus and for sharing our mission to develop and deliver
therapies that extend the lives of patients living with life-altering illnesses. Every decision we make, every milestone, and every challenge
we overcome, is with the well-being of patients in mind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We will have a Company-wide Conference Call later today to discuss
this transaction with you in more detail.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Denny</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dennis M. Lanfear</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chief Executive</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Coherus BioSciences</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Information and Where to Find It</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the proposed transaction, the Company expects to
file with the SEC a proxy statement on Schedule 14A, and it may also file other documents regarding the proposed transaction with the
SEC. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the definitive proxy statement and a proxy
card to each stockholder entitled to vote at the special meeting relating to the proposed transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY THE PROXY
STATEMENT AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS
INCORPORATED BY REFERENCE THEREIN,&nbsp;IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION, RELATED MATTERS AND THE PARTIES TO THE PROPOSED TRANSACTION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may obtain a free copy of the proxy statement and other relevant
documents (if and when they become available) that are or will be filed with the SEC for free at the SEC&rsquo;s website at www.sec.gov.
Copies of the documents filed with the SEC by the Company will be available free of charge on the Company&rsquo;s website at https://investors.coherus.com/sec-filings
or by contacting the Company&rsquo;s Investor Relations Department at IR@coherus.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Participants in the Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company and certain of its directors and executive officers and
other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction.
Information about the directors and executive officers of the Company, including a description of their direct or indirect interests,
by security holdings or otherwise, is set forth in the proxy statement for its 2024 Annual General Meeting, which was filed with the SEC
on April&nbsp;15, 2024 and other documents that may be filed from time to time with the SEC. Other information regarding the participants
in the proxy solicitations and a description of their direct and indirect interests in the proposed transaction, by security holdings
or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC regarding the proposed transaction
when such materials become available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>From:</B> Jodi Sievers<BR>
<B>Sent:</B> Tuesday, December&nbsp;3, 2024<BR>
<B>To:</B> [***]<BR>
<B>Cc:</B> Melissa Gibson Denny [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Subject:</B> CHRS announcement today + call with management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hi [***],</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Coherus today <U>announced</U> the planned divestiture of UDENYCA
to Intas Pharmaceuticals,&nbsp;Ltd. for up to $558 million ($483 million of which is upfront). This transaction allows us to focus sharply
on LOQTORZI commercialization as well as our innovative combination I/O portfolio development programs with LOQTORZI which include casdozokitug,
and CHS-114, our CCR8 inhibitor. The proceeds will allow us to pay down in its entirety our $230M convertible note, substantially improving
our balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are hosting a <U>conference call this morning at 8:00 am ET / 5:00
am PT</U> related to the transaction. To access the conference call, please pre-register through the following link to receive dial-in
information and a personal PIN to access the live call: <U>https://register.vevent.com/register/BId14c70118ce44561902dd39c791136fa</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please dial in 15 minutes early to ensure a timely connection to the
call.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please let me know if you have time to catch up with management this
morning following the conference call. The team will be available at approximately 8:45 am ET and throughout the day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thank you,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jodi</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jodi Sievers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">VP,&nbsp;Investor Relations&nbsp;&amp; Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TEL</B> &nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">333 Twin Dolphin Drive, Suite&nbsp;600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Redwood City, CA 94065</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2429853d3_defa14aimg01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements in this communication include express or implied forward-looking
statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act about the proposed transaction
between Coherus BioSciences,&nbsp;Inc. (the &ldquo;Company&rdquo;) and Intas Pharmaceuticals Ltd. (&ldquo;Intas&rdquo;) that involve risks
and uncertainties relating to future events and the future performance of the Company and the UDENYCA business. Forward-looking statements
relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning
matters that are not historical facts.&nbsp; Words such as &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo;
 &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;future,&rdquo; &ldquo;opportunity,&rdquo;
 &ldquo;likely,&rdquo; &ldquo;target,&rdquo; variations of such words, and similar expressions or negatives of these words are intended
to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. You can also
identify forward-looking statements by discussions of strategy, plans or intentions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of such forward-looking statements include, but are not limited
to, express or implied statements regarding: the asset purchase agreement and related matters, including, but not limited to, the ability
to satisfy the closing conditions to consummate the proposed transaction at all or in the estimated time; prospective performance and
opportunities with respect to the Company or the UDENYCA business; post-closing operations and the outlook for the Company or the UDENYCA
business; the Company&rsquo;s targets, plans, objectives or goals for future operations, including those related to the UDENYCA business,
product candidates, research and development, and product candidate approvals; future receipt of sales milestone payments from the proposed
transaction; projections of or targets for cost savings related to transfers of employees and reductions in indebtedness; projections
of the amount of time that the Company&rsquo;s will be able to operate using its cash balance and proceeds from the proposed transaction;
statements about the potential uses of proceeds from the transaction and the assumptions underlying or relating to such statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements are based on the Company&rsquo;s current
plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general
and specific, assumptions and changes in circumstances, many of which are beyond the control of the Company. A number of important factors,
including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking
statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation:
uncertainties as to the timing for completion of the proposed transaction; uncertainties as to the Company&rsquo;s ability to obtain the
approval of its stockholders required to consummate the proposed transaction; the possibility that competing offers will be made by third
parties; uncertainties of payment of the earn-outs in the future; the occurrence of any event, change or other circumstance that may give
rise to a right of one or both of Intas and the Company to terminate the Asset Purchase Agreement; the possibility that the proposed transaction
may not be completed in the time frame expected by the Company including on a timely basis or at all, including due to the possibility
that a governmental entity may prohibit, delay, or refuse to grant approval, if required, for the consummation of the proposed transaction
(or only grant approval subject to adverse conditions or limitations);&nbsp; the proposed transaction disrupts the Company&rsquo;s current
plans and operations or diverts the attention of the Company&rsquo;s management or employees from ongoing business operations; the risk
that the Company may not realize the anticipated benefits of the proposed transaction in the time frame expected, or at all; the effects
of the proposed transaction on relationships with the Company&rsquo;s employees, suppliers, business or collaboration partners or governmental
entities, or other third parties as a result of the proposed transaction; the ability to retain and hire key personnel; significant or
unexpected costs, charges or expenses resulting from the proposed transaction; the potential impact of unforeseen liabilities, future
capital expenditures, revenues, costs, expenses, earnings, economic performance, indebtedness, financial condition and losses on the future
prospects, business and management strategies for the management, expansion and growth of the Company after the consummation of the proposed
transaction; potential negative effects related to this announcement or the consummation of the proposed transaction on the market price
of the Company&rsquo;s common stock and/or the Company&rsquo;s operating or financial results; uncertainties as to the long-term value
of the Company&rsquo;s common stock; and the nature, cost and outcome of any litigation and other legal proceedings involving the transaction,
the Company or its directors, including any legal proceedings related to the proposed transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While the foregoing list of factors presented here is considered representative,
no list should be considered to be a complete statement of all potential risks and uncertainties. There can be no assurance that the transaction
described above will in fact be consummated in the manner described or at all. For a further discussion of these and other factors that
could cause the Company&rsquo;s future results to differ materially from any forward-looking statements see the section entitled &ldquo;Risk
Factors&rdquo; in the Company&rsquo;s Quarterly Report on Form&nbsp;10-Q for the period ended September&nbsp;30, 2024, filed with the
SEC on November&nbsp;6, 2024, as updated by the Company&rsquo;s subsequent periodic reports filed with the SEC and, when available, the
proxy statement of the Company relating to the proposed transaction. Any forward-looking statements speak only as of the date of this
communication and are made based on the current good faith beliefs and judgments of the Company&rsquo;s management, and the reader is
cautioned not to rely on any forward-looking statements made by the Company. Unless required by law, the Company is not under any duty
and undertakes no obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or
factors, of new information, data or methods, future events or other changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Information and Where to Find It</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the proposed transaction, the Company expects to
file with the SEC a proxy statement on Schedule 14A, and it may also file other documents regarding the proposed transaction with the
SEC. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the definitive proxy statement and a proxy
card to each stockholder entitled to vote at the special meeting relating to the proposed transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY THE PROXY
STATEMENT AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS
INCORPORATED BY REFERENCE THEREIN,&nbsp;IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION, RELATED MATTERS AND THE PARTIES TO THE PROPOSED TRANSACTION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may obtain a free copy of the proxy statement and other relevant
documents (if and when they become available) that are or will be filed with the SEC for free at the SEC&rsquo;s website at <U>www.sec.gov</U>.
Copies of the documents filed with the SEC by the Company will be available free of charge on the Company&rsquo;s website at <U>https://investors.coherus.com/sec-filings
</U>or by contacting the Company&rsquo;s Investor Relations Department at <U>IR@coherus.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Participants in the Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company and certain of its directors and executive officers and
other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction.
Information about the directors and executive officers of the Company, including a description of their direct or indirect interests,
by security holdings or otherwise, is set forth in the proxy statement for its 2024 Annual General Meeting, which was filed with the SEC
on April&nbsp;15, 2024 and other documents that may be filed from time to time with the SEC. Other information regarding the participants
in the proxy solicitations and a description of their direct and indirect interests in the proposed transaction, by security holdings
or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC regarding the proposed transaction
when such materials become available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>From:</B> Jodi Sievers<BR>
<B>Sent:</B> Tuesday, December&nbsp;3, 2024<BR>
<B>To:</B> [***]<BR>
<B>Cc:</B> Melissa Gibson Denny [***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Subject:</B> CHRS announcement today + call with management</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Hi [***],</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Coherus today <U>announced</U> plans to divest UDENYCA to Intas Pharmaceuticals,&nbsp;Ltd.
for up to $558 million ($483 million of which is upfront). This transaction allows us to focus sharply on LOQTORZI commercialization
as well as our innovative combination I/O portfolio development programs with LOQTORZI which include casdozokitug, and CHS-114, our CCR8
inhibitor. The proceeds will allow us to pay down in its entirety our $230M convertible note, substantially improving our balance sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We are hosting a <U>conference call this morning at 8:00 a.m.&nbsp;ET
/ 5:00 a.m.&nbsp;PT</U> related to the transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">We look forward to meeting with you later this morning at the Citi
conference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Thank you,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jodi</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Jodi Sievers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">VP,&nbsp;Investor Relations&nbsp;&amp; Corporate Communications</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>TEL</B> &nbsp;[***]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">333 Twin Dolphin Drive, Suite&nbsp;600</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Redwood City, CA 94065</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><IMG SRC="tm2429853d3_defa14aimg01.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The statements in this communication include express or implied forward-looking
statements within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act about the proposed transaction
between Coherus BioSciences,&nbsp;Inc. (the &ldquo;Company&rdquo;) and Intas Pharmaceuticals Ltd. (&ldquo;Intas&rdquo;) that involve risks
and uncertainties relating to future events and the future performance of the Company and the UDENYCA business. Forward-looking statements
relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning
matters that are not historical facts.&nbsp; Words such as &ldquo;will,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;should,&rdquo;
 &ldquo;expect,&rdquo; &ldquo;plan,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;believe,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;predict,&rdquo; &ldquo;project,&rdquo; &ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;future,&rdquo; &ldquo;opportunity,&rdquo;
 &ldquo;likely,&rdquo; &ldquo;target,&rdquo; variations of such words, and similar expressions or negatives of these words are intended
to identify such forward-looking statements, although not all forward-looking statements contain these identifying words. You can also
identify forward-looking statements by discussions of strategy, plans or intentions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Examples of such forward-looking statements include, but are not limited
to, express or implied statements regarding: the asset purchase agreement and related matters, including, but not limited to, the ability
to satisfy the closing conditions to consummate the proposed transaction at all or in the estimated time; prospective performance and
opportunities with respect to the Company or the UDENYCA business; post-closing operations and the outlook for the Company or the UDENYCA
business; the Company&rsquo;s targets, plans, objectives or goals for future operations, including those related to the UDENYCA business,
product candidates, research and development, and product candidate approvals; future receipt of sales milestone payments from the proposed
transaction; projections of or targets for cost savings related to transfers of employees and reductions in indebtedness; projections
of the amount of time that the Company&rsquo;s will be able to operate using its cash balance and proceeds from the proposed transaction;
statements about the potential uses of proceeds from the transaction and the assumptions underlying or relating to such statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">These forward-looking statements are based on the Company&rsquo;s current
plans, estimates and projections. By their very nature, forward-looking statements involve inherent risks and uncertainties, both general
and specific, assumptions and changes in circumstances, many of which are beyond the control of the Company. A number of important factors,
including those described in this communication, could cause actual results to differ materially from those contemplated in any forward-looking
statements. Factors that may affect future results and may cause these forward-looking statements to be inaccurate include, without limitation:
uncertainties as to the timing for completion of the proposed transaction; uncertainties as to the Company&rsquo;s ability to obtain the
approval of its stockholders required to consummate the proposed transaction; the possibility that competing offers will be made by third
parties; uncertainties of payment of the earn-outs in the future; the occurrence of any event, change or other circumstance that may give
rise to a right of one or both of Intas and the Company to terminate the Asset Purchase Agreement; the possibility that the proposed transaction
may not be completed in the time frame expected by the Company including on a timely basis or at all, including due to the possibility
that a governmental entity may prohibit, delay, or refuse to grant approval, if required, for the consummation of the proposed transaction
(or only grant approval subject to adverse conditions or limitations);&nbsp; the proposed transaction disrupts the Company&rsquo;s current
plans and operations or diverts the attention of the Company&rsquo;s management or employees from ongoing business operations; the risk
that the Company may not realize the anticipated benefits of the proposed transaction in the time frame expected, or at all; the effects
of the proposed transaction on relationships with the Company&rsquo;s employees, suppliers, business or collaboration partners or governmental
entities, or other third parties as a result of the proposed transaction; the ability to retain and hire key personnel; significant or
unexpected costs, charges or expenses resulting from the proposed transaction; the potential impact of unforeseen liabilities, future
capital expenditures, revenues, costs, expenses, earnings, economic performance, indebtedness, financial condition and losses on the future
prospects, business and management strategies for the management, expansion and growth of the Company after the consummation of the proposed
transaction; potential negative effects related to this announcement or the consummation of the proposed transaction on the market price
of the Company&rsquo;s common stock and/or the Company&rsquo;s operating or financial results; uncertainties as to the long-term value
of the Company&rsquo;s common stock; and the nature, cost and outcome of any litigation and other legal proceedings involving the transaction,
the Company or its directors, including any legal proceedings related to the proposed transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">While the foregoing list of factors presented here is considered representative,
no list should be considered to be a complete statement of all potential risks and uncertainties. There can be no assurance that the transaction
described above will in fact be consummated in the manner described or at all. For a further discussion of these and other factors that
could cause the Company&rsquo;s future results to differ materially from any forward-looking statements see the section entitled &ldquo;Risk
Factors&rdquo; in the Company&rsquo;s Quarterly Report on Form&nbsp;10-Q for the period ended September&nbsp;30, 2024, filed with the
SEC on November&nbsp;6, 2024, as updated by the Company&rsquo;s subsequent periodic reports filed with the SEC and, when available, the
proxy statement of the Company relating to the proposed transaction. Any forward-looking statements speak only as of the date of this
communication and are made based on the current good faith beliefs and judgments of the Company&rsquo;s management, and the reader is
cautioned not to rely on any forward-looking statements made by the Company. Unless required by law, the Company is not under any duty
and undertakes no obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or
factors, of new information, data or methods, future events or other changes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Information and Where to Find It</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the proposed transaction, the Company expects to
file with the SEC a proxy statement on Schedule 14A, and it may also file other documents regarding the proposed transaction with the
SEC. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the definitive proxy statement and a proxy
card to each stockholder entitled to vote at the special meeting relating to the proposed transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY THE PROXY
STATEMENT AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS
INCORPORATED BY REFERENCE THEREIN,&nbsp;IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION, RELATED MATTERS AND THE PARTIES TO THE PROPOSED TRANSACTION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may obtain a free copy of the proxy statement and other relevant
documents (if and when they become available) that are or will be filed with the SEC for free at the SEC&rsquo;s website at <U>www.sec.gov</U>.
Copies of the documents filed with the SEC by the Company will be available free of charge on the Company&rsquo;s website at <U>https://investors.coherus.com/sec-filings
</U>or by contacting the Company&rsquo;s Investor Relations Department at <U>IR@coherus.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Participants in the Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company and certain of its directors and executive officers and
other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction.
Information about the directors and executive officers of the Company, including a description of their direct or indirect interests,
by security holdings or otherwise, is set forth in the proxy statement for its 2024 Annual General Meeting, which was filed with the SEC
on April&nbsp;15, 2024 and other documents that may be filed from time to time with the SEC. Other information regarding the participants
in the proxy solicitations and a description of their direct and indirect interests in the proposed transaction, by security holdings
or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC regarding the proposed transaction
when such materials become available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">From: John Holland</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">To: Commercial Team Email</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">December&nbsp;3, 2024</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Subject: FDM: Coherus Divestiture of UDENYCA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Commercial team,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Please find attached the approved Field Direction Memo (FDM) that provides
direction on how to engage with customers about the Coherus Divestiture of UDENYCA Franchise to Intas Pharmaceuticals. This document has
been shared for your review in advance of our Commercial Call that will take place today at 12:00 PM ET / 9:00 AM PT. Please DO NOT engage
with customers on the divesture until we conduct our Commercial Call</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For any questions you may have, please reach out to me at [***].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Regards,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">John Holland</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">SVP, Marketing&nbsp;&amp; New Product Planning</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Additional Information and Where to Find It</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">In connection with the proposed transaction, the Company expects to
file with the SEC a proxy statement on Schedule 14A, and it may also file other documents regarding the proposed transaction with the
SEC. Promptly after filing its definitive proxy statement with the SEC, the Company will mail the definitive proxy statement and a proxy
card to each stockholder entitled to vote at the special meeting relating to the proposed transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">INVESTORS AND SECURITY HOLDERS ARE URGED TO READ CAREFULLY THE PROXY
STATEMENT AND OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO AND ANY DOCUMENTS
INCORPORATED BY REFERENCE THEREIN,&nbsp;IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION, RELATED MATTERS AND THE PARTIES TO THE PROPOSED TRANSACTION.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">You may obtain a free copy of the proxy statement and other relevant
documents (if and when they become available) that are or will be filed with the SEC for free at the SEC&rsquo;s website at www.sec.gov.
Copies of the documents filed with the SEC by the Company will be available free of charge on the Company&rsquo;s website at https://investors.coherus.com/sec-filings
or by contacting the Company&rsquo;s Investor Relations Department at IR@coherus.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Participants in the Solicitation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company and certain of its directors and executive officers and
other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction.
Information about the directors and executive officers of the Company, including a description of their direct or indirect interests,
by security holdings or otherwise, is set forth in the proxy statement for its 2024 Annual General Meeting, which was filed with the SEC
on April&nbsp;15, 2024 and other documents that may be filed from time to time with the SEC. Other information regarding the participants
in the proxy solicitations and a description of their direct and indirect interests in the proposed transaction, by security holdings
or otherwise, will be contained in the proxy statement and other relevant materials to be filed with the SEC regarding the proposed transaction
when such materials become available.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>tm2429853d3_defa14aimg001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2429853d3_defa14aimg001.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" !( ;4# 2(  A$! Q$!_\0
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M+H?B#XK:G:RP!XM1NM%U/7_#ND>%M =)!+'K'CG6]$L+\!_["?4YXXXJP?\
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MW4G^8/\ GV.*JK>(&*_OC@E<D9&0<<'=G_'KBJ=I?07,7FPSQR0[005W+OR
M48.)I%9&Z@/ZC))J(O*=[2/>PIO;:7>-5(R=K(8G5/*8<KN8';][&,#YM4W&
MHH5<+55:=X27,[04==5S*.[MI%2OH[[+](A7A7H_7,(Z6/P;C>G.&+HX6,):
M\TW5JRC"I%Q5N6[Y?C?NM-[(EW=#@'GYA(I'_?)_ETIV=XP&=2!U#'&?7KD
M>^21USBN:.N64<TEJM_;2W,*1O+&]]"LJK(3AO+P04P#M =V !&6<@G;BE8Q
MI,'#"=(Y%(=EC$9 (93R<$-G."S$C/ XTG3KT9I5,/*E3E%.C.;:=237-RJ,
MHW:Y;23U35[.R9&'Q>&Q"E/#YA@I3I7=>A2S'!8^5%)\MJBPU6HZ+4[Q;J**
M<O<2<KHMJI0#+NW^\6(.?<\__6[T\,V <=@3SDXXSQDX]^./:LS[;%+D+,QV
MN&#Y1HRN3P@AEW,!D F4!3]X\9%4AJEM,\D<5R&\J5;2ZV31&>VG:)Y0C[9C
M LS^=9&*, RE)E+J5="LNEBO>;P_M4M^5-.*>SELDF]%;6_G9"GC\OE*+EF5
M"+DW&*4XZRC9O16O9;[F^S8[./8$_P B.GTIC$, 6:1.>-K'GTS@CMU]?3(S
M56*Y2<(T,K;'&Y"6A>-\C+*'B:3!3! (?!(RID K/N;V*R0-/,Y#.2&:7:8[
M6VD,DDTGVJ;:\(#JDT\:F0JZY8_*4BC&4JDH0P\Z=1)<RFI:^\U:-W)733<E
M960ZV)I8?#U,8\=1=*DH:^ZX_O)*"OO=.]U\W?1FV6."#N"XX8,=P]\ Y_#M
M[<FHHY&W,%5V"D@%F8YQD9.2?3Z=?>J.^95WRRMY:H')&\YP#M"^7(K>62#M
M$SNY7'FEI <YUMKVFWLQM8-4@>YC=XY((I828F5BK)(@E,P9""K!1D,,$ C)
MU>%K55SQH2JQH^_/V;J6A>+5YN"Y>EK3:C?;WM#+$8W!X6MA\/B<WPN%GBX*
MM0C6E2A*NYV]RESN+D[-2M&[2=[6.F9LC)W9]%)'\L_X5*O0=>@Z]>G?W]:J
M*'6( ."Q4?/DX/;J23UXY/NW-6DSL3)R=JY(Z$X&2/QKGBXR<I*E4IROROGN
MDTGT7,X[]E>V[Z'?HGRQO*/*FJM[J=W;3IM[VE]&AU%%%6,**** "BBB@ KX
MP_:R^&?Q.^(?A">P\#W.FWMG9WD6JWO@^Y:]LF\4"U_M9GM?[2%S'%!+YL]@
M\$(4K-+;*_R[8B/L^O+OB#X+T?Q_X3\4^"]?2_BTWQ'8:E:2W>G7DMCJUAYH
M>%=<T75;>+S]-U?1B\&H:+=6TD-Y8WUI#/:RF6-'3Y#CO@?)O$?AC,^"L^QN
M;9?E>?T7@L7B\BKRPN;4J,I4YS^KUE1Q%*>'ER0688+%TJF S'!J6"QU.>'J
M-+V.'^(\;PGGF6<09;3HU\?EV(]KA,)BZ5.I@<54E"5)T<0ZR=.C-TZE3ZK7
MC*GBJ6(ES8.K3Q'+-?G#X9U?]F3XE_$WPS>?'SP)-X*^*/PUT&+P;X<\*?$F
M:3_A7&AHEW;ZBFH:7H.IJWAM-<N#%I\$5]J<,KR"QM!IDT"@9_4JUCM'@MY(
MXD"1^5&DD9*A)%4*%B7)V*G"HNXA%"KNX!'X7?LX>(M;^)'Q@^*_[ G[;[1^
M,OC#\.?-U7X,_&&6P_LWQ%XT\!+I\*-=V?B2/RY;Z]'AC4='\0W0U.6ZU'4K
MR;Q;;:F\]YX1MS'[]JFB_M?_ +'UTNH?#\:Q^TM\&?M<EK-X(O+:[N?B#X<L
M;>7RXTT6WM(Y;FYBM+7RHXH=&CU"TN!&#!9:#!LCB^*S7'>+W@_A<LX7X]H_
M\1"\..',DP=+ACC;A/!^QSG)<IE4P6'P%#%^&>'J9IEN,Y:%*A&IGW#$\/#$
M3HSA6R7!UZ2E'[/)?#OPKXVSK-,=X;T<C\,./.+,95Q_$7"/$.)HY;0XQSOV
M3K5YX3C;&TZ"P^(C&3K4\'QEG--NC4I8? YCR34#Y#_X+_H$\+_L++\@/_#9
MG@>5@HE!\^.!8DF;S,J9%BNKA(WC.52XN$!"RL&J_P#!=-_"\=Y^Q_#\+K;5
MF_;6B^+5C>_ .W\&013>+AHMF;6XO(S81[%%F/'3>"8_#LFHOLA\27=XEL\>
MG?VY(?-_^"ROQ2'QA^#_ /P3]\6S>#/''P^D?]M?P3IFI>&OB9X=O_!?B.VN
MHK2UWM;Z=JC7%SJ5F9\K#<6=S)#>*K.LLBA9)/N+X/?LI>)?B5_P4X_:-_;
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M!8\*!RV6. !GG JK:Z=96=K%:VMK:P6T$-M;P00P10PP068'V6"&)$5(HK;
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MYVZCFIW=_P!<O*M[M,7 C;,4B2P.H>*6-EP(KB-E99$VG:R2!U*D*1BOQ?\
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CDJS<ZF)KU)OEA>4ZE6I4G-^XKRG.<YRD]92E*3;;;?\ _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>tm2429853d3_defa14aimg002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2429853d3_defa14aimg002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  K ,,# 2(  A$! Q$!_\0
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M@J"Y,7C8\DJBJ2C>=*C*HU3I*C%Q52K*2:JWBI04;O\ T0/@=_P6R\>>-O\
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M[TW]G6WM=9THH=1\.7/B;Q.(8=5TXS*R&]TB6\2[M#*K(;B",N""0?VHT/\
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M+'T:N#J\(</3S&KED<YRVK@_88[,5B:F(QF7T74Q$8TJ%7&QIT:>%I_SQ_\
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>tm2429853d3_defa14aimg003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2429853d3_defa14aimg003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  ] .,# 2(  A$! Q$!_\0
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MYJ]TFT+<ZA((T(4E5)BAABBMHRPRZAW4_O 3ZOC@\#.2>>Y&0/\ / YR*ZO
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M%W\*4UA#XVM8X/A+'//HS6\ZR".31/"MMK64N7MY%6POK.?<JEI'B#POY?\
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M&;$6D&GV^OZU8VT;ZUXOU:PT:*"/2] L+IU\[3]-66YF^W6FFV$K32N\=?\
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MN+KQCX.ELO*)U*:\26_BL=/>X@AU"RUW7=!DEV:K ;?]3G7>I [\=B,9!/\
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MPSD^=8:LJM&G)6H\M.--0OQK%/&DL3&2*15=2#\CHW*LIZ;<X92I'R^V15X
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M\M([F&;R=7COO$7C'Q??Z4CQJUQIECHX@U16:*XNFM[6?3M3_4_X2_LP:5\
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MR7QC+=^!/#[/K7@O6O"OA+6?AKXET;Q4"-9MM3_X2J&-(+\OK)L-2.KV5O\
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MU9;&:4V,EW9K>")IX W>^)?V-/@%XW_L"+QYI/Q(^(.G>&=:TSQ%I6@?$/\
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MVH:CJ5]=ZCJ-[/+=WUU<7$C2GN#'&=V44[R"^5&'(  +CHY 50"V2 H Q@4
M?SA_"SX0:?:^ ?VO%\6_#?\ ;JL_"*?M4?!_XF?#KXB+:Z_JO[5G@ Z-\+M(
MM=-^-T*>,)-5\0>,;K2-1%[H6MZ3I>E>.?%5KH^MW%OJGAFT2QN(-&^TOV7O
MBM\2/$?QR\)>%/"GQ0^)G[3WPL_X1/QE)\0?'_QL_9@U'X%^)/A$EGI^E?\
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MSALH(+:VBCM[:VACMK:")"B16\*)'!$%(!18DCQM "G=GVJUY:848.%(( +
=9 VC(! 8  <,".,XS3\]?8X_0'^M !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>tm2429853d3_defa14aimg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm2429853d3_defa14aimg01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  J *D# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^LG7?$ND
M^&[;S]4NTA4YVKU9OH*DU[6(- T2ZU.X&4@0MM'5L=A7R5K^O7_B/5)+_4)F
MDD<\ G(4>@]!6D(<QA5J\FVY].:?\0]"U+PY>ZY"\XM;/<)%=0'.!G@9QSVY
MJ;PYX\T#Q0=FGW>)AUAE&U_YD?K7B?A;0=0NOA5XCN(D;8[*RC^\$!+8_!A7
MG=M<SV5S'<6\KQ31L&1T."I'O5^S3N8NO)6;1]JT5QWPV\6GQ;X86><_Z9 Y
MAF]R #N_7]*Z;4M0ATNPENYR=D:YP.I/85ERMRY5N=3J14.=O0MT5PT&I^*?
M$.9].6&TM2<*9._X@4D^K>)O#KI+JBPW5H2 S1=OQ(KJ^IROR\RYNU]3SO[2
MIVY^27+_ #6T]>]OD=U156"_MY]/CO0X6%UW;CVJFOB?16E\H:C"7SC'-<RI
MS=[)Z'>Z]*-FY)7VU-:BL'Q;<O%X4NY[:9D;"%7C;!^\.A%-TK6;6S\/64NH
MW@1GC'S2$DFM%1DZ?.N]K&,L5"-9TI::7OTWL=!15:RU"TU"+S+2=)4]5J.]
MU>PT['VNZCBSTW&LN25^6VINZL%'G;5N]]"[15&QUC3]2)%G=1RD=0IJ1]1L
MX[L6CW"+.1D(>N*'"2=FM056#7,I*WJ6J*H#6M.,$DXNX_*C;:[=@?3]*N12
MI/$LL;!D<95AW%#C);H<:D)?"[CZ*K1ZA:2W;VL<ZM.GWD'456NO$&DV4WE7
M%]%')_=)IJG-NR1,JU.*YG)6]32HJ*WN(;J$2P2+)&>C+4M0U;1FB::NCSOX
MU-(OP^?R\\W,8;'IALUX?X)M/#5YJI3Q'=2PQ97RPH^5NN=S9R.W8U]-^*="
M3Q)X=N],<A6F0A&/\+8X-?(^HZ==:3?RV5Y$T4\1PRFNBGJK'%B$U-2/HQI=
M8LM6L;/3+2".P"8AAA/[IE[YX'\JX/QEH_P_@U-O,O9;2[/,T-C&)44_B5Q4
M7A+Q?J%E\*]<A25R]J52"3=S&) 1P>V-M>6 /-)@99V/U)-;2ESV5K6[=3EA
M#V=VY.7-KKT/I?X56?ABUTVY/AZ\EN'9AY_F\$>G&2!^=:GQ#$G]@+MSLWC=
M^8Q5#X3^$Y?#/A??=KMO+M_-<8Y5< !?T)_&NTU"QAU*QEM+A=T<BX/M[UC2
MJ*G64WK9G77HRK8:5):-HCT@PG2+4P8\ORQC'Z_K3]0:R6RD.H"(VW&\2C*]
M>,CZUR,.A>)=")CTJ\BFM<Y5)<Y'X<BB70/$6O2HNKW<45J""T<6>?PZ5M["
M'/S^T5OQ^[N<JQ=54_9^Q?-:W3E^_L5O$<D%_J6DZ19.D>FS#?B(;5/S'/'X
M?G722^$M&:P-N+*%3MP)0@W9]<U7UKPHE]9VHLI!!<V@ B;'H<__ %ZI/#XS
MEMS:-):J"-IF!.<?7%:\_/"*ISY;;W=NN_F<_LW3JS=:ES<UK65UMMY:G/17
M,R^%-<TYY"\5M(%C)/0"0"NC\.>&K"[T:WN;V,7$LB#[XR%'8 4K>$9+?PG=
MV$$BRWEP59Y&X!.X'^E;^B6DMAH]M:S;?,C0!MIXJJ^(CR/V;Z_HM?O)P>"D
MJL?;QNE'KJE[ST^2.-TF%=&\;:E;6I(A%NS!,\=C67HDOVZ[N=0O-*EU*21S
MC.&5<GI@UV$.A72^,KG4W\LVLL6P<G/;MCVJD?#VLZ)?SW&ASQ&"9B6ADR,=
M^.M:JO!WUU:6NWJKHYWA*L;/E?+&4M$D]]G9Z-&+>6]R-4M;W2]$FL71OF"@
M!2/H*MZ_9O?^/HK593$)(E#,.H'M6G#H^OZIJ$5QJUTD-O%R(H2?F^O2K5SH
MEW+XTBU1?+^S*@4Y)S_*I]O&,MU=1?GZ:O<KZI.4':+LYQ>J2T6[LMBCXITJ
MTTGPC)#9Q;$,BY]3P:Z+0/\ D 6'_7%?Y4:WI:ZQI4MF6V%N5;&<&N;T_3_%
MUI FGK<6R0(-HEY) ]N*YDU5H\KEJG?4]"47A\5SQ@W%Q25ELTR/2/G\?ZKM
M;'##([5EV=DFA2W"ZWHYO$=LBX50_'MFM_2?"]Q8:]>3NRFUE0HK!CN/N:A@
MTWQ3HQD@L[B&ZMV;*F4DD?H:ZO:QNU&2V76VWF>?]7J**E.#NI2>B4MWU3W3
M[E_P?'IT=E/_ &;=/+$S[C&XP4/YUTM<WX4\/W.C"ZGO)$:>Y(W+'T '_P"N
MNDKSL2XNJW%W\SV\"I1P\5./*^P5S/BKP)HOBZ,&_@"W"C"SQC#CZGN/:NFH
MK!.VQUM)JS."TKX6Z=IGA/4M"^U-+]M))G,>"G&%XSSCD]>]/\*_"K0?#,ZW
M14WMVA!6651A2.A YP?>NZHI\S)]G'30****DL**** "BBB@ HHHH **** "
2BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
